All sponsors

Shenyang Sunshine Pharmaceutical Co., LTD.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS10
PHASE 3 / 2-30
RECRUITING5
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO0%

Delay Index: of 6 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Shenyang Sunshine Pharmaceutical Co., LTD. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Injection of humanized nerve growth factor (NGF) antibody
NCT07008703
P1/2RecruitingCancer Pain1322025-12
SSS17 Capsule (6 Dose Levels)
NCT07007936
P2Not yet recruitingPostoperative Anemia; Arthroplasty, Replacement, Hip902026-04
SSGJ-706
NCT07171606
P2RecruitingFirst-line Advanced NSCLC Patients2402026-08-31
SSGJ-706+XELOX
NCT07233850
P2Not yet recruitingGastric/Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Cancer (CRC)3002026-12
SSGJ-705
NCT07022002
P2RecruitingLocally Advanced, Recurrent or Metastatic Malignancies3402026-12-31
SSGJ-705
NCT07646626
P2RecruitingLocally Advanced (Unresectable) or Metastatic Solid Tumors1502027-06-30
SSGJ-706
NCT07874984
P2Not yet recruitingNon Small Cell Lung Cancer2202027-11
SSS06
NCT06854276
P2Not yet recruitingChemotherapy-induced Anemia; Non-myeloid Malignancies802027-12-01
SSGJ-612 (HER2-targeted antibody)
NCT07757230
P2RecruitingMetastatic Breast Cancer872028-02
SPGL008
NCT07445308
P1/2Not yet recruitingNMIBC1202028-11-21